Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia.
Armitage
J
J
Clinical Trial Service Unit, Richard Doll Building, Old Road Campus, University of Oxford, Oxford OX3 7LF, UK. jane.armitage@ctsu.ox.ac.uk
D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D000069438:Ezetimibe; D005260:Female; D006579:Heterozygote; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D017410:Practice Guidelines as Topic; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D001384:Azetidines; D008055:Lipids; D000069438:Ezetimibe